MaxCyte
MXCT
112 hedge funds and large institutions have $111M invested in MaxCyte in 2025 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 32 increasing their positions, 41 reducing their positions, and 24 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.33% less ownership
Funds ownership: 67.06% → 65.73% (-1.3%)
7% less funds holding
Funds holding: 120 → 112 (-8)
22% less repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 41
29% less capital invested
Capital invested by funds: $156M → $111M (-$45M)
29% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$3.66M |
| 2 |
MFS
Mirabella Financial Services
London,
United Kingdom
|
+$2.78M |
| 3 |
WIC
Willis Investment Counsel
Gainesville,
Georgia
|
+$838K |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$798K |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$657K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Axa
Paris,
France
|
-$4.8M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.13M |
| 3 |
Chevy Chase Trust
Bethesda,
Maryland
|
-$2.54M |
| 4 |
SAM
Silvercrest Asset Management
New York
|
-$2.34M |
| 5 |
RA
Royce & Associates
New York
|
-$1.43M |
MXCT Hedge Fund Activity: Q3 2025 in Review
112 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in MaxCyte (MXCT) for Q3 2025, worth a combined $111M — down 29% from $156M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of MXCT and 17 opened new positions — a net loss of 7 holders — while 41 trimmed existing stakes and 32 added.
The largest buyer was Kennedy Capital Management, opening a new position worth an estimated $3.66M. The largest seller was Axa, exiting entirely with an estimated $4.8M sold.
- 112 institutional investors held MaxCyte (MXCT) as of Q3 2025, down from 120 in Q2 2025.
- Funds reported $111M of MaxCyte stock for Q3 2025, down 29% quarter-over-quarter.
- 17 funds opened new MaxCyte positions in Q3 2025 and 24 closed out, a net change of -7 holders.
- The largest MaxCyte buyer in Q3 2025 was Kennedy Capital Management, an estimated $3.66M added.
- The largest MaxCyte seller in Q3 2025 was Axa, an estimated $4.8M sold.
Based on aggregated 13F filings for Q3 2025.